Navigation Links
Sunesis Reports Financial Results for the Second Quarter 2009
Date:7/29/2009

of the investors in the private placement, among other conditions, and the common stock of the private placement may be sold upon approval by the company and a majority of the investors in the private placement, among other conditions.
  • At the American Society of Clinical Oncology (ASCO) 2009 Annual Meeting in June, the company presented new data from three ongoing clinical trials demonstrating that voreloxin shows promising safety and efficacy in AML and in platinum-resistant ovarian cancer. These presentations can be found on the Sunesis website at http://www.sunesis.com/products-in-development/presentations.php
    • REVEAL-1 (Response Evaluation of VorEloxin in AmL) is a Phase 2 dose regimen optimization study of single agent voreloxin in newly diagnosed elderly AML patients who are unlikely to benefit from standard induction chemotherapy. Interim clinical data from this study continue to show that voreloxin can induce durable complete remissions across several dosing schedules.
    • The Phase 1b/2 trial is designed to evaluate the safety, pharmacokinetics and anti-leukemic activity of escalating doses of voreloxin when administered on days one and four with cytarabine given either as a continuous infusion of 400 mg/m2 daily for five days (CIV Schedule) or as a two hour IV bolus of 1 g/m2 daily for five days (Bolus Schedule). Across both the CIV and Bolus Schedules, a total of 14 patients with primary refractory AML were enrolled and treated with a voreloxin dose of 80 mg/m2 or higher. Five of 14 of these patients achieved a CR or CRp for an overall CR or CRp rate of 36 percent, which compares favorably relative to expected remission rates in this AML population of approximately 10 to 15 percent. In the Bolus Schedule, both first rela
      '/>"/>

    SOURCE Sunesis Pharmaceuticals, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11

    Related biology technology :

    1. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
    2. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
    3. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
    4. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
    5. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
    6. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
    7. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
    8. Sunesis Pharmaceuticals to Report Financial Results for the First Quarter on May 8, 2008
    9. Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (Formerly SNS-595)
    10. Sunesis Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
    11. Sunesis to Present at Upcoming Conferences
  • Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/19/2014)... (PRWEB) December 19, 2014 Charm Sciences ... test for the Detection of Aflatoxin M1 in raw ... receive independent third party validation. The peer reviewed report ... of the Institute for Agricultural and Fisheries Research (ILVO-T&V) ... , Aflatoxin B1, the most toxic aflatoxin and ...
    (Date:12/19/2014)... , Dec. 19, 2014  Roche (SIX: RO, ... Bina Technologies, Inc. (Bina), a privately held company ... , USA. Bina provides a big data platform ... sequencing (NGS) data. Bina,s proprietary on-market Genomic Management ... academic researchers to perform fast and scalable analyses ...
    (Date:12/19/2014)... 19, 2014 Research and Markets ... the "Technology Innovations in Smart Fabrics (Technical ... http://photos.prnewswire.com/prnh/20130307/600769 The ... offers a detailed assessment on technological advancements and ... 1. The Smart Fabrics market ...
    (Date:12/19/2014)... (PRWEB) December 18, 2014 LayerBio is ... ophthalmology and wound care. The National Eye Institute (NEI) ... LayerBio a Phase I SBIR grant to develop a ... are the most common cause of vision loss in ... blindness worldwide. According to Dr. Ken Mandell, LayerBio’s Founder ...
    Breaking Biology Technology:Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2Roche acquires Bina Technologies and enters the genomic informatics market 2Roche acquires Bina Technologies and enters the genomic informatics market 3Technology Innovations in Smart Fabrics (Technical Insights) 2LayerBio Awarded NIH Grant to Develop a Drug Delivery Device for Cataract Surgery 2
    ... French . , A new nanotech catalyst developed by McGill ... offers industry an opportunity to reduce the use of ... to facilitate and drive chemical reactions. Although chemists have ... of traditional chemical catalysts and do attempt to reuse ...
    ... BERWYN, Pa. , Feb. 16 Encorium Group, ... research organization (CRO) conducting studies in over 30 countries for ... announced that it had filed a Certificate of Amendment to ... the State of Delaware to affect a reverse ...
    ... , , SAN FRANCISCO , Feb. 16 ... sector will showcase innovative new initiatives at Informex this week, ... world-class solutions to the global chemicals industry. , At Informex ... unprecedented partnership between seven leading universities, the private sector and ...
    Cached Biology Technology:Encorium Group, Inc. Announces One-for-Eight Reverse Stock Split 2Encorium Group, Inc. Announces One-for-Eight Reverse Stock Split 3Encorium Group, Inc. Announces One-for-Eight Reverse Stock Split 4Encorium Group, Inc. Announces One-for-Eight Reverse Stock Split 5Encorium Group, Inc. Announces One-for-Eight Reverse Stock Split 6Scotland Launches Chemicals Industry Partnerships To Propel $13 Billion Sector 2Scotland Launches Chemicals Industry Partnerships To Propel $13 Billion Sector 3Scotland Launches Chemicals Industry Partnerships To Propel $13 Billion Sector 4
    (Date:12/17/2014)... Research and Markets ( http://www.researchandmarkets.com/research/s6qzt5/samsung_galaxy_s5 ... "Samsung Galaxy S5 - Home Button Synaptics Fingerprint ... http://photos.prnewswire.com/prnh/20130307/600769 ... than the iPhone 5S, Samsung introduces for the ... The Galaxy S5 home button presents ...
    (Date:12/17/2014)... 2014  Automation is fundamentally transforming the travel ... at international borders. Over the past decade, ePassports, ... veteran travelers to self process through border control ... at an increasing number of airports, seaports, and ... According to Maxine Most , Principal at ...
    (Date:12/11/2014)... 10, 2014  Data Sciences International (DSI), the ... a new series of digital telemetry implants to ... M series, part of the PhysioTel™ Digital platform, ... possible physiologic data when incorporating functional endpoints into ... to toxicology studies has evolved from short ECG ...
    Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2New telemetry implants expected to change how large animal toxicology studies are conducted 2
    ... of Alabama at Birmingham (UAB) departments of Pathology, Microbiology and ... Heart, Lung, and Blood Institute (NHLBI) to study so-called red ... changes in red blood cells that have been stored for ... focus on the mechanisms by which red blood cell storage ...
    ... August of 2008 Jacob Schaefer, PhD, on vacation in San Diego, ... it happened, the newspaper was running a series on the wildfires ... more frequent they now occur every few years instead of ... The more intense fire cycle is fueled by cheatgrass (Bromus tectorum), ...
    ... BOSTON, Mass. (June 20, 2010) By emulating nature,s ... Biologically Inspired Engineering, Harvard Medical School and Dana-Farber Cancer ... and can be programmed to move and change shape ... nanodevices are highly suitable for medical applications because DNA ...
    Cached Biology News:NHLBI grants $1.47 million to study red blood cell transfusion storage times and bioactivity 2In elevated carbon dioxide, soybeans stumble but cheatgrass keeps on truckin' 2In elevated carbon dioxide, soybeans stumble but cheatgrass keeps on truckin' 3In elevated carbon dioxide, soybeans stumble but cheatgrass keeps on truckin' 4In elevated carbon dioxide, soybeans stumble but cheatgrass keeps on truckin' 5Researchers create self-assembling nanodevices that move and change shape on demand 2
    ... of gene expression) technology allows ... profiles generated by SAGE are ... transcripts making it possible to ... Kit is designed to make ...
    Sheep Serum US Origin...
    ... For the ultimate in utility and ... to meet the needs of the researcher. ... interior dimensions or as sheet material that ... enclosures. These isolators are autoclavable and non-cytotoxic ...
    2,4-Dinitrophenyl hapten is conjugated to Human Serum Albumin (HSA) protein through lysine....
    Biology Products: